Moreover, as ERβ correlates with better response to chemotherapy in breast cancer [45], we investigated whether the ERβ-specific agonist DPN enhances p53 tumor suppressor activity in chemotherapy-treated cells. The gene discussed is TP53; the disease is breast cancer.